Trial · NCT01451827
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 | Tolvaptan MR 50 mg | -2.46 | Standard Deviation 4.40 | Percentage change | |
| Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 | Tolvaptan MR 80 mg | -2.55 | Standard Deviation 3.85 | Percentage change | |
| Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 | Tolvaptan IR 60/30 mg | -1.17 | Standard Deviation 4.52 | Percentage change | |
| Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3 | Placebo | 0.09 | Standard Deviation 5.31 | Percentage change | |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 50 mg | Urinary Frequency | 0.74 | Standard Deviation 0.94 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 80 mg | Urinary Frequency | 0.82 | Standard Deviation 0.83 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan IR 60/30 mg | Urinary Frequency | 0.99 | Standard Deviation 0.78 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Placebo | Urinary Frequency | 0.10 | Standard Deviation 0.35 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 50 mg | Urinary Urgency | 0.69 | Standard Deviation 0.96 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 80 mg | Urinary Urgency | 0.66 | Standard Deviation 0.77 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan IR 60/30 mg | Urinary Urgency | 1.01 | Standard Deviation 0.95 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Placebo | Urinary Urgency | 0.05 | Standard Deviation 0.30 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 50 mg | Nocturia | 0.97 | Standard Deviation 1.28 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan MR 80 mg | Nocturia | 1.15 | Standard Deviation 0.89 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Tolvaptan IR 60/30 mg | Nocturia | 1.36 | Standard Deviation 1.12 | Unit on a scale |
| Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) | Placebo | Nocturia | 0.11 | Standard Deviation 0.59 | Unit on a scale |
| Percent Change From Baseline in TKV at Week 8. | Tolvaptan MR 50 mg | -2.04 | Standard Deviation 3.87 | Percentage change | |
| Percent Change From Baseline in TKV at Week 8. | Tolvaptan MR 80 mg | -2.02 | Standard Deviation 3.54 | Percentage change | |
| Percent Change From Baseline in TKV at Week 8. | Tolvaptan IR 60/30 mg | -0.08 | Standard Deviation 7.31 | Percentage change | |
| Percent Change From Baseline in TKV at Week 8. | Placebo | 2.13 | Standard Deviation 7.99 | Percentage change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01451827/results